COMMUNIQUÉS West-GlobeNewswire

Medifirst Solutions to Present at the American Pain Association Conferences Focusing on Medical CBD and the Opioid Epidemic

11/12/2018 - 14:30

Freehold, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared [...]

MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients

11/12/2018 - 14:30

MYK-491 Demonstrated Increase in Contractility Consistent with Data from Preclinical and Healthy Volunteer Studies Multiple-Ascending Dose Phase 2a Clinical Trial in DCM and Systolic Heart Failure Patients Underway [...]

Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting

11/12/2018 - 14:27

EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]

Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer

11/12/2018 - 14:05

HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/ [...]

Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)

11/12/2018 - 14:02

TORONTO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has formed a 100% owned subsidiary in Australia, named Arch Clinical Pty [...]

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer

11/12/2018 - 14:00

Interim analysis expected as early as Q2 2020 Newark, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael), a leader in the growing field of cancer metabolism-based therapeutics, today announced [...]

NexImmune Granted Key US Patent for Core E+E Technology

11/12/2018 - 14:00

GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office has issued a new [...]

ImmuCell Announces USDA Approval of Dual-Force™ First Defense®

11/12/2018 - 14:00

PORTLAND, Maine, Dec. 11, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]

Shockwave Announces collaboration With Abiomed on Physician Training

11/12/2018 - 14:00

Abiomed Invests $15 Million in Shockwave SANTA CLARA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Shockwave Medical, a pioneer in the development and commercialization of intravascular lithotripsy to treat complex [...]

Operation Hat Trick Donates $10,000 to SoldierStrong

11/12/2018 - 14:00

Nonprofit Organizations Share Purpose of Supporting Injured Veterans STAMFORD, Conn. and HAMPTON, N.H., Dec. 11, 2018 (GLOBE NEWSWIRE) -- SoldierStrong, a nonprofit organization dedicated to providing advanced medical [...]

Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation

11/12/2018 - 14:00

Funding to Help Further Clinical Development of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a [...]

HealthLynked to Attend the 2019 HIMSS Global Conference & Exhibition

11/12/2018 - 14:00

NAPLES, Fla., Dec. 11, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK) today announced that the Company will be attending the HIMSS Global Conference & Exhibition ( Healthcare Information and Management [...]

eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)

11/12/2018 - 14:00

SAN DIEGO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it has dosed [...]

Comfort Launch by Vergence Naturals Exceeds Expectations

11/12/2018 - 14:00

VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update on the recent soft-launch of its [...]

CLS Holdings USA, Inc Announces Receipt for Final Prospectus From Ontario Securities Commission and Conditional Approval to List on the Canadian Securities Exchange

11/12/2018 - 14:00

LAS VEGAS, Dec. 11, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “ CLS ,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada [...]

Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit

11/12/2018 - 14:00

Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by improvement on the [...]

T1D Exchange Names New Board Members

11/12/2018 - 13:45

Expanded Board to Strengthen Type 1 Diabetes Expertise and Philanthropic Reach BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- T1D Exchange , a nonprofit, research organization dedicated to accelerating therapies and [...]

Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia

11/12/2018 - 13:35

Patents granted in five countries protect the Company’s novel technology and intratumoral, immune cell-activating product candidates, including INT230-6 WESTPORT, Conn., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intensity [...]

Helius Medical Technologies, Inc. Announces Exercise of Underwriters’ Overallotment Option

11/12/2018 - 13:05

NEWTOWN, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”) announced today that the underwriters of its previously announced public offering of [...]